In Vivo Methods to reduce hypercholesterolemia and improve vascular dysfunction
AssigneeExocell, Inc.
InventorsMargo P. Cohen, Rex S. Clements
Life of this patent
Estimating the term…
Abstract
The present invention is directed to the prevention in vivo of post-secretory Amadori modifications in the Apo B molecule, as well as methods of using compounds that protect against these modifications in vivo to treat hypercholesterolemia and vascular dysfunction.
Claims7
A method of treating a living being having hypercholesterolemia which is caused by Amadori-modified Apo B in serum of the living being comprising the steps of:
- administering in a therapeutically acceptable carrier to the living being a therapeutically effective amount of diclofenac which protects against post-secretory modification of Apo B and lowers the living being's serum concentration of Amadori-modified Apo B.
A method of lowering serum concentrations of Amadori-modified Apo B in a living being comprising the step of administering to the living being a therapeutically effective amount of diclofenac.
A method of treating a living being having vascular dysfunction which is reflected by increased protein in the urine of the living being comprising the steps of:
- administering a therapeutically effective amount of diclofenac of about 100-300 mg/day to the living being which protects against post-secretory modification of Apo B in vivo, lowers the living being's serum concentration of Amadori-modified Apo B, and reduces urine protein excretion.
Dependencies are inferred from the claim text.